General News Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference EN September 14, 2020
General News Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September EN September 11, 2020
General News Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) EN September 1, 2020
General News Regulated Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 9, 2020
General News Regulated Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 5, 2020
General News Regulated Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME EN January 7, 2020
General News Oxurion NV Announces the Passing of Dr. Claude Sander, Chief Legal Officer and Corporate Secretary to the Board EN December 21, 2019
General News Regulated Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME EN December 19, 2019
General News Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco EN October 9, 2019
General News Regulated Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME EN September 9, 2019
General News Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) EN September 4, 2019
General News Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019 EN September 2, 2019
General News Regulated Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME EN August 20, 2019
General News Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME EN July 1, 2019
